



## Xeris Pharmaceuticals Announces Exercise of Underwriters' Option to Purchase Additional Shares

February 20, 2020

CHICAGO--(BUSINESS WIRE)--Feb. 20, 2020-- Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize ready-to-use injectable and infusible drug formulations, today announced that, in connection with its previously announced underwritten public offering of shares of common stock, the underwriters partially exercised their option to purchase an additional 1,299,769 shares of common stock from the Company out of the 1,350,000 total shares underlying the option. The exercise of this option increased the size of the offering to an aggregate of 10,299,769 shares at a price to the public of \$4.15 per share. The aggregate gross proceeds of the offering were approximately \$42.7 million, before deducting underwriting discounts and commissions and other offering expenses. The purchase of additional shares of common stock closed on February 20, 2020.

Jefferies, Piper Sandler, RBC Capital Markets and Mizuho Securities acted as joint book running managers for the offering.

The shares of common stock were offered pursuant to a shelf registration statement on Form S-3 (File No. 333-233061), including a base prospectus, filed by Xeris on August 6, 2019 and declared effective by the Securities and Exchange Commission, or SEC, on August 21, 2019. A final prospectus supplement and accompanying prospectus related to the offering was filed with the SEC on February 13, 2020 and is available at the SEC's website at [www.sec.gov](http://www.sec.gov). A copy of the final prospectus supplement and accompanying prospectus can be obtained from Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, NY 10022; by phone at (877) 821-7388; or by email at [Prospectus\\_Department@Jefferies.com](mailto:Prospectus_Department@Jefferies.com); Piper Sandler & Co., Attn: Prospectus Department, 800 Nicollet Mall, J12S03, Minneapolis, Minnesota 55402; by phone at (800) 747-3924; or by email at [prospectus@psc.com](mailto:prospectus@psc.com); RBC Capital Markets, LLC, Attention: Equity Syndicate Department, 200 Vesey Street, 8th Floor, New York, NY 10281; by phone at (877) 822-4089; or by email at [equityprospectus@rbccm.com](mailto:equityprospectus@rbccm.com); or Mizuho Securities USA LLC, Attention: Equity Capital Markets, 1271 Avenue of the Americas, 3rd Floor, New York, NY 10020; by phone at (212) 205-7600; or by email at [US-ECM@mizuhogroup.com](mailto:US-ECM@mizuhogroup.com).

This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any offer or sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

### About Xeris Pharmaceuticals, Inc.

Xeris is a specialty pharmaceutical company delivering innovative solutions to simplify the experience of administering important therapies that people rely on every day around the world.

With a novel technology platform that enables ready-to-use, room-temperature stable formulations of injectable and infusible therapies, the company is advancing a portfolio of solutions in various therapeutic categories, including its first commercial product, Gvoke™. Its proprietary XeriSol™ and XeriJect™ formulation technologies have the potential to offer distinct advantages over conventional product formulations, including eliminating the need for reconstitution, enabling long-term, room-temperature stability, significantly reducing injection volume, and eliminating the requirement for intravenous (IV) infusion. With Xeris' technology, new product formulations are designed to be easier to use by patients, caregivers, and health practitioners and help reduce costs for payers and the healthcare system.

### Forward-Looking Statements

Any statements in this press release about future expectations, plans and prospects for Xeris Pharmaceuticals, Inc., including statements about Xeris' public offering, the expected use of proceeds from the offering, future expectations, plans and prospects for the Company and other statements containing the words "may," "will," "could," "should," "expects," "intends," "target," "contemplates," "plans," "anticipates," "believes," "estimates," "predicts," "projects," "potential," or "continue," and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including, without limitation: uncertainties related to the market acceptance of Gvoke™ and any other product candidates, if approved, the regulatory approval of its product candidates, its ability to market and sell its products, if approved, and other factors discussed in the "Risk Factors" section of Xeris' Annual Report on Form 10-K for the year ended December 31, 2018, which is on file with the SEC, as updated by any subsequently filed SEC filings, including Xeris' Quarterly Reports on Form 10-Q, and the "Risk Factors" section of Xeris' prospectus supplement and accompanying prospectus related to this public offering. Any forward-looking statements contained in this press release speak only as of the date hereof, and Xeris expressly disclaims any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.

View source version on businesswire.com: <https://www.businesswire.com/news/home/20200220005729/en/>

Source: Xeris Pharmaceuticals, Inc.

Allison Wey  
Senior Vice President, Investor Relations and Corporate Communications  
[awey@xerispharma.com](mailto:awey@xerispharma.com)  
312-736-1237